INVO Bioscience, Inc. Stock

Equities

INVO

US44984F4019

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
1.37 USD -9.87% Intraday chart for INVO Bioscience, Inc. +68.10% +1.48%
Sales 2024 * 14.84M Sales 2025 * 28.61M Capitalization 3.76M
Net income 2024 * -4M Net income 2025 * - EV / Sales 2024 * 0.25 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.13 x
P/E ratio 2024 *
-4.72 x
P/E ratio 2025 *
-137 x
Employees 16
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.16%
More Fundamentals * Assessed data
Dynamic Chart
1 day-9.87%
1 week+68.10%
Current month+21.24%
1 month+34.31%
3 months+30.48%
6 months+132.20%
Current year+1.48%
More quotes
1 week
0.70
Extreme 0.7
3.50
1 month
0.70
Extreme 0.7
3.50
Current year
0.70
Extreme 0.7
3.50
1 year
0.50
Extreme 0.5
10.50
3 years
0.50
Extreme 0.5
108.55
5 years
0.50
Extreme 0.5
273.54
10 years
0.50
Extreme 0.5
953.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 17-10-10
Director of Finance/CFO 56 21-06-13
Chief Tech/Sci/R&D Officer - 20-02-12
Members of the board TitleAgeSince
Director/Board Member 56 19-12-15
Director/Board Member 64 20-09-13
Corporate Secretary 55 08-09-30
More insiders
Date Price Change Volume
24-04-19 1.37 -9.87% 1,395,750
24-04-18 1.52 -16.48% 5,048,023
24-04-17 1.82 +139.47% 226,638,759
24-04-16 0.76 -0.91% 3,854,086
24-04-15 0.767 -5.89% 24,362

Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT

More quotes
INVO Bioscience, Inc. is a healthcare services fertility company. The Company is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. It operates three INVO Centers in North America.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.37
Average target price
-
Consensus